Inflammation
Our ambition
Our ambition is to develop novel immunotherapies that will significantly improve the lives of people with autoimmune and chronic inflammatory diseases such as rheumatoid arthritis, lupus, inflammatory bowel disease, and psoriatic arthritis. Novo Nordisk has established a state-of-the-art inflammation research site in Seattle, and we have a number of innovative monoclonal antibody projects in clinical development within autoimmune and inflammatory diseases.
Our partnering focus
Novo Nordisk is committed to building a presence in treating autoimmune and chronic inflammatory diseases.
We welcome first-in-class protein and peptide opportunities from research to clinical stage and focus on the following targets:
- Molecules on the surface of cells involved in immune regulation
- Cytokines
Read more about Biopharmaceuticals Research Unit
Contact us
For further information please contact Biopharmaceuticals Sourcing
